Navigation Links


Inhibition in Biological Technology

Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... Pharmacodynamic monitoring has demonstrated inhibition of PI-3 kinase activity at doses as low as 1 mg ... progressing patients, as well as clearcut inhibition of PI-3 kinase activity, even in the early ... where it leads to increased proliferation and inhibition of apoptosis (programmed cell death). PX-866 has ...

Oncothyreon's PX-866 is effective in preclinical model of pulmonary fibrosis

... seen in the model. These results suggest that inhibition of the PI-3 kinase pathway might be beneficial in ... where it leads to increased proliferation and inhibition of apoptosis (programmed cell death). PX-866 has been shown to induce prolonged inhibition of tumor PI-3 kinase signaling following both ...

Telik Reports Preclinical Results at AACR Annual Meeting

... associated with aneuploidy and carcinogenesis. inhibition of Aurora kinase activity induces growth arrest and apoptosis in cells and leads to tumor-growth inhibition in xenograft models of human cancer. Key ... drug candidates showing strong and equipotent inhibition of Aurora kinase and VEGFR kinase, with IC50s ...

Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research

... lines indicate that perifosine treatment induced inhibition of Akt phosphorylation, and decreases of cell ... Targeting breast cancer stem cells through inhibition of PI3-K/Akt/B-catenin signaling Author(s): ... and that targeting of cancer stem cells through inhibition of this signaling pathway represents a rational ...

Isis and Partners Present New Research at the American Association for Cancer Research 2009 Annual Meeting

... its collaborators presented results on antisense inhibition of novel targets that could offer new mechanisms ... new preclinical data showing that antisense inhibition of STAT5 resulted in potent anti-tumor activity. ... a Marker for Carcinomas" showed that antisense inhibition of Malat-1 altered the splicing of multiple ....

Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology

... Lead Oral Candidate Demonstrates Proteasome inhibition and Anti-Tumor Activity SOUTH SAN ... resulted in rapid and prolonged dose-dependent inhibition of the proteasome. Furthermore, significant proteasome inhibition was achieved at doses well below the ...

Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS

... 2008 issue of the magazine. Entitled "Efficient inhibition of the Alzheimer's disease Beta-secretase by ... Unlike existing approaches for Beta-secretase inhibition that do not account for the ... In this instance, by directing inhibition to the sub-compartment where the enzyme is ...

FASgen, Inc. Presents Ovarian Cancer Efficacy and Toxicology Data to the American Association for Cancer Research

... have shown that pharmacological FAS inhibition is cytotoxic to a variety of human xenograft ... with published in vitro studies where inhibition of FAS pathway activity by at least 20% led to ... new therapeutic products based on the selective inhibition of fatty acid biosynthesis. The Company has the ...

ARIUS presents new findings for anti-cancer antibody programs at AACR

... human pancreatic cancer model (78.7% tumor growth inhibition at 2 mg/kg compared to control group). ... effects in an AML tumor model (57% tumor growth inhibition at a 10 mg/kg compared to control group). ... Moreover, apoptosis is achieved through inhibition of the AKT pathway, commonly believed to be an ...

Celadrin(R) Research Unveiled at Nutrigenomics 2008 Meeting in Paris, France

... was found to exert strong receptor binding inhibition using a standard radio binding assay. "The ... those of the white blood cells coupled with inhibition of thromboxane production or receptor inhibition suggests that Celadrin(R) influences the ...

Option to Develop Exelixis Compound Exercised By Genentech

... trial and subsequent clinical development. "MEK inhibition is an exciting approach to cancer therapy. The ... oral administration of XL518 results in sustained inhibition of ERK phosphorylation in multiple preclinical ... in clinical trials, with significantly less MEK inhibition in the brain. XL518 shows dose-dependent tumor ...

EntreMed Announces 2008 Corporate and Clinical Program Priorities

... antitumor activity, including tumor growth inhibition or regression in multiple preclinical models. ... Akt-mTOR signaling pathway, which occurs through inhibition of the mTOR/rictor branch of the pathway. ... profile, including antiproliferative activity and inhibition of angiogenesis. ENMD-2076 has demonstrated ...

Replidyne Announces 2007 Fourth Quarter and Full Year Results

... an IND candidate from our DNA replication inhibition program. Finally, we will continue to seek ... research programs, primarily its C. difficile and inhibition of DNA replication programs offset by ... within the C. difficile and inhibition of DNA replication programs. These increases were ...

Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial

... mechanistic toxicities in the liver (where MTP inhibition causes fatty liver) and other organs. ... but avoids the mechanistic toxicities of MTP inhibition in the liver and other organs such as the heart, ... by limiting the uptake of dietary fat through inhibition of the triglyceride transport function of MTP in ...

XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain

... has a unique ratio of reuptake inhibition of serotonin versus norepinephrine, which ... another SNRI with a unique ratio of reuptake inhibition of serotonin versus norepinephrine to offer to my ... members of the SNRI class in its unique ratio of inhibition reuptake of serotonin versus norepinephrine ...

Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association

... alone. Initial responses improved with continued therapy. Potent inhibition of the proteasome has been observed and the lenalidomide/dexamethasone ... proteasome inhibitors. Carfilzomib produces specific and sustained inhibition of the proteasome, leading to apoptosis in cancer cells with minimal ...

Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models

... resistance patterns in neuroblastoma cell lines, highlighting AT-101's inhibition of Mcl-1, also presented - MALVERN, Pa., April 21 /PRNewswire/ -- ... Ascenta's small molecule pan-Bcl-2 inhibitor, AT-101, had preferential inhibition in Mcl-1 predominant lines. They concluded that compounds with activity ...

Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR

... of prematurity model in mice Overview: Examined the inhibition of the VEGF/VEGFR pathway with AMG 273 and the inhibition of the angiopoietin/Tie2 pathway with AMG 386 Lead author: Estrada ...

Buckyballs could keep water systems flowing

... activities. "As the concentration of buckyballs increased, so did the inhibition of respiration," Chae said. "This respiratory inhibition and anti-attachment suggests that this nanoparticle may be useful as an ...

ImQuest Presentations at CROI Report Significant Advances in Therapeutic and Microbicide Product Development Programs

... exhibits characteristics of an ideal microbicide, including the inhibition of two early steps in the viral replication pathway as well as its lack of ... but may also possess important therapeutic benefits in the context of the inhibition of highly drug resistant virus strains," said Dr. Buckheit. "We are ...

AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences

... that have potent anti-angiogenic / anti-tumor activity through inhibition of the action of the Id proteins. The Chairman of the Board of AngioGenex, ... the absence of the Id genes in animals results in a highly significant inhibition of tumor growth and a reduction in the size of mature tumors. The research ...

Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology

... targets several serine proteases including Cathepsin G, an enzyme whose inhibition may play a role in neuropathic pain. Proteolix researchers believe that ... proteasome inhibitors. Carfilzomib produces specific and sustained inhibition of the proteasome, leading to apoptosis in cancer cells with minimal ...

RNAi Helps Illuminate the Inner Workings of the Cell Cycle: Synthetic RNAissance™ Genes Created by DNA2.0 Enable Key Research

... simultaneously optimized for expression in the desired host and to escape inhibition by siRNA that is targeted to the natural gene. ... simultaneously optimized for expression in the desired host and to escape inhibition by siRNA that is targeted to the natural gene. DNA2.0 guarantees ...

Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International

... patients. These include receptor-mediated targeting of tumor cells and inhibition of thymidylate synthase, a key enzyme involved in cell growth and ... believe that BGC 945 (ONX 0801) may represent the next era in anti-folate inhibition and has the potential to be the first targeted therapy of its class with ...

Oncothyreon announces prioritization plan for development programs

... prostate and melanoma, where it leads to increased proliferation and inhibition of apoptosis (programmed cell death). PX-866 has been shown to induce prolonged inhibition of tumor PI-3 kinase signaling following both oral and intravenous ...

SuperGen Reports 2008 Second Quarter Financial Results

... causing a reduction in phospho-BAD levels and enhancement of mTOR inhibition in vitro. SGI-1776 induced significant tumor regression in MV-4-11 ... and mutant JAK2 activity in cancer cell lines, resulting in inhibition of STAT5 phosphorylation as well as a reduction in Bcl-XL ...

Oncothyreon initiates Phase 1 trial of PX-866 cancer compound

... prostate and melanoma, where it leads to increased proliferation and inhibition of apoptosis (programmed cell death). PX-866 has been shown to induce prolonged inhibition of tumor PI-3 kinase signaling following both oral and intravenous ...

GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections

... deep experience in antibacterial research and has validated efflux pump inhibition for potentiation of antibacterial activity, as well as expanding the ... intracellular antibiotic concentrations achieved through efflux pump inhibition can increase the potency and pharmacological barrier against other drug ...

Oncothyreon files investigational new drug application for PX-866 oncology compound

... prostate and melanoma, where it leads to increased proliferation and inhibition of apoptosis (programmed cell death). PX-866 has been shown to induce prolonged inhibition of tumor PI-3 kinase signaling following both oral and intravenous ...

ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting

... (p < 0.05) after 44 days. The study also demonstrated a dose dependent inhibition of tumor growth, with the 400mg/kg dose being the most effective, ... a reduction of inflammation and cancer cell proliferation through inhibition of NF-kappaB in prostate cancer and inhibition of TNF-alpha, and ...

Oncothyreon's PX-478 is effective in preclinical model of human lung cancer

... humans. Treatment with oral PX-478 for five days resulted in significant inhibition of tumor growth, marked reduction in lymph nodes metastases, decreased ... orally in animal models, and has shown marked tumor regressions and growth inhibition in model systems across a range of cancers, including lung, ovarian, ...

Oncothyreon highlights corporate and clinical objectives for 2008

... orally in animal models and has shown marked tumor regressions and growth inhibition in such model systems across a range of cancers, including lung, ovarian, ... types of human cancer. The PI-3-kinase inhibitor PX-866 induces prolonged inhibition of tumor PI-3-kinase signaling following both oral and intravenous ...

Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure

... innovative combination. Tekturna HCT incorporates the latest direct renin inhibition technology and offers an important new option for patients who need ... mg tablets. The long-term potential of Tekturna and direct renin inhibition is being studied in an extensive clinical program known as ASPIRE ...

Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.

... of Hope. -- 20050244858 Methods and Compositions for the Specific inhibition of Gene Expression by Double-Stranded RNA -- 20050277610 Methods and Compositions for the Specific inhibition of Gene Expression by Double-Stranded RNA About Nastech's RNA-Based ...

ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting

... recombinant human monoclonal antibody which has shown a beneficial partial inhibition of the blood coagulation Factor VIII. Its long half life of approximately ... a stable and long-acting inhibition. This indicates well-controlled inhibition of Factor VIII activity with low risk of spontaneous bleeding, thus ...

Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial

... tumors. In addition, data was presented that demonstrated tumor growth inhibition of TPI 287 when delivered orally in subcutaneous mouse xenograft models ... inhibit tumor cell growth in a number of in vitro cell lines and has shown inhibition of human tumor growth in certain animal xenograft models when tested ...

AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment

... improved; - An interesting difference to the AEZS-112 profile is the inhibition of topoisomerase I by compounds 2 and 3. Moreover, compound 2 displayed significant higher potency for topoisomerase II inhibition than AEZS-112; - In vitro plasma and liver microsomal stability of the ...

Novel Alternative Approach to Inhibiting Insulin Growth Factor (IGF) May Provide New Treatment for Breast Cancer and Other Cancers

... CTI. "Many of the current approaches target blocking the IGF receptor or inhibition of post receptor kinases in an attempt to slow or kill tumor cell growth and are often associated with inhibition of insulin's important metabolic functions including maintaining normal ...

Rigel to Present Research Programs at Scientific Conferences

... and invasion of tumor cells. The data to be presented shows that Axl inhibition may suppress tumor growth via multiple mechanisms. Rigel has potent, small ... in Breast Cancer Research in San Diego, October 17-20, 2007. Selective inhibition of PLK1 could be important in cancer treatment. Rigel has discovered a new ...

Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients

... -- specific ETA receptor antagonism: ZD4054 targets the ETA receptor. inhibition of this receptor is thought to be related to multiple processes that drive ... cancer (HRPC) and bone metastases. (2) Morris, C.D. et al. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical ...
Other Contentsbronchitisbronchitisbronchitisbronchoscopybronchoscopybronchiolitisbronchiolitisbrucellosisbruisesbruisesbubonicbubonicbubonicrecluse
(Date:11/24/2009)...evel action of a remarkable class of ring-shaped p...th the Lawrence Berkeley National Laboratory (Berk...lography beamline at the Advanced Light Source (AL...e expression and replication, and are vital to the...ctious agents, such as the human papillomavirus, w...
(Date:11/24/2009)... NEW YORK (November 24, 2009) -- The Wildlife C... revealing that the last remaining population of S...ue to the rising tide of poaching and habitat loss...form Russian officials of what needs to be done to...est cat. , The report was released ...
(Date:11/24/2009)...tutes fish food is a matter of debate. A high-prof...almost 50 percent of their carbon from trees and l...terrestrial and aquatic ecosystems. , But new re...s is not likely to be true. Algae provide a much r...ing to research published this week in the Procee...
Breaking Biology News(10 mins):Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4Report shows dramatic decline in Siberian tigers 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3Nile Therapeutics Inc To Raise 243 4 Million in Private Placement 12937 1Nile Therapeutics Inc To Raise 243 4 Million in Private Placement 12937 2Nile Therapeutics Inc To Raise 243 4 Million in Private Placement 12937 3Nile Therapeutics Inc To Raise 243 4 Million in Private Placement 12937 4Meatless Burgers Hot Dogs Not Always Full of Veggies 51049 1Meatless Burgers Hot Dogs Not Always Full of Veggies 51049 2Hip Arthroscopy Procedures to Soar Through 2013 51045 1Hip Arthroscopy Procedures to Soar Through 2013 51045 2
(Date:11/30/2009)... MINNEAPOLIS, Nov. 30 A new study ...emental Medicare insurance customers have a curren...Medicare coverage. The figure is up from 20% in 2...switch" measure has been a leading indicator of ac... some intention to switch actually will leave thei...
(Date:11/30/2009)...he House and Senate bills stack up , , M...reform bills moving through the U.S. Congress diff...a dramatic reduction in the number of uninsured Am... Representatives earlier this month would expand c...preparing to debate a proposal to expand coverage ...
(Date:11/30/2009)... To best serve our patients, their ca...ed with the Institute of Women,s Health of North A...accination. This service is available to all indiv... visit our website to locate a convenient LOCATIO... (Vocus) November 30, 2009 -- Accordin...
(Date:11/30/2009)... Exiqon A/S (NASDAQ OMX Copenhagen: &... Medical School ICCB-Longwood Screening Facility (...g Center of Excellence. ICCB-L supports investiga...pitals and institutions, for high-throughput scree... Boston, MA and Copenhagen, Den...
(Date:11/30/2009)...iddle-aged men and women who engage in high levels...amage to their knees and increasing their risk for...day at the annual meeting of the Radiological Soci... that people with higher physical activity levels ...lities and, thus, at higher risk for developing os...
Breaking Medicine News(10 mins):Health News:More Seniors Considering Health Insurance Switch 2Health News:Health Reform: What's in It for You? 2Health News:Health Reform: What's in It for You? 3Health News:2009 H1N1 Influenza Vaccination Being Offered at Various Affiliated Campuses of the Institute of Women's Health of North America in Florida 2Health News:2009 H1N1 Influenza Vaccination Being Offered at Various Affiliated Campuses of the Institute of Women's Health of North America in Florida 3Health News:Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Health News:Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3Health News:Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 4Health News:Too much physical activity may lead to arthritis 2
Other TagsAtfAtfAtfAtfRefillOther Tagsadequate 2adequate 3adequate 4adequate 5adequate 6adequate 7adequate 8adequate 9adequate 10ward 2ward 3ward 4ward 5ward 6ward 7ward 8ward 9sepsis 2pull 2pull 3pull 4pull 5underlying 2underlying 3underlying 4underlying 5underlying 6underlying 7underlying 8underlying 9underlying 10combines 2combines 3